LLY241220P685000
- 0.15
- -0.16-51.61%
Eli Lilly and Co Newsroom
Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com
Insurer Stocks Tumble. Trump Echoes Drug Industry Attacks on PBMs. -- Barrons.com
Moderna Remains the Most Shorted Among S&P 500 Healthcare Stocks in November
Express News | Trump: 'We're Going to Knock Out the Middlemen' Who Are Keeping Drug Prices High
Express News | Trump: Does Not Like Mandates for Vaccines, When Asked Whether Schools Should Mandate
Express News | Trump: I'm a Big Believer in Polio Vaccine
Another Week, Another Index Record | Lkive Stock
Why the Investor Craze for Ozempic and Rival Weight-loss Drugs May Resume Next Year
The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect
INNOVENT BIO (01801) has reached a commercialization cooperation with Eli Lilly and Co regarding a new cancer drug based on BTK inhibitors.
On December 16, INNOVENT BIO (01801) and Eli Lilly and Co jointly announced the following cooperation agreement regarding Eli Lilly's non-covalent (reversible) BTK inhibitor, Jaypalta (100 mg and 50 mg tablets), in mainland China: INNOVENT BIO will be responsible for the import, sales, promotion, and distribution of Jaypalta; Eli Lilly will be responsible for the research and development as well as post-marketing medical affairs related work.
Express News | Innovent Biologics Inc - Lilly to Manage R&D and Post-Market Medical Affairs for Jaypirca
Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca (Pirtobrutinib) in Mainland China
Eli Lilly (NYSE:LLY) Is Increasing Its Dividend To $1.50
Why Is Eli Lilly and Company (LLY) Among the Best Income Stocks to Buy According to Analysts?
Weekly Buzz: Tech stocks hit high scores on ominous day
Express News | "Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
Market Mixed on Friday the 13th | Livestock
Eli Lilly's Mounjaro Won't Have Separate Indication for Obstructive Sleep Apnea, European Regulator Says
Eli Lilly's Manjaro Gains on Novo Nordisk's Wegovy in UK
EMA: Eli Lilly and Co (LLY.US) weight loss drug Mounjaro can also treat sleep apnea without the need for additional indications.
An expert panel of the EU pharmaceutical regulatory institution EMA has determined that Eli Lilly and Co's weight-loss drug Mounjaro does not require a separate indication for the treatment of obstructive sleep apnea (OSA).